Access to medicines and treatment: latest news

Access to medicines and treatment resources

Access to medicines and treatment features

Access to medicines and treatment news from aidsmap

More news

Access to medicines and treatment news selected from other sources

  • MSM and transgender people are absent from the Global Fund country dialogue in Eastern Europe and Central Asia

    Men who have sex with men (MSM) and transgender people (TG) are not involved in strategic discussions around HIV in most nations of Eastern Europe and Central Asia (EECA). Lack of reliable epidemiological data, high stigma, and policies that restrict the access of MSM and TG to information on HIV preclude the two key populations from meaningfully participating in the country dialogue processes.

    17 hours ago | EATG
  • Aetna to Lower Costs for Most HIV Drugs After Complaint

    Aetna Inc. has agreed to reduce out-of-pocket payments for most HIV and AIDS medicines after pressure from an advocacy group, revising coverage that had some patients paying $1,000 a month for the drugs.

    30 March 2015 | Bloomberg
  • Guidance on overseas visitors hospital charging regulations

    Guidance for NHS bodies in carrying out their duties under the NHS (Charges to Overseas Visitors) Regulations 2015 to make and recover charges for NHS hospital treatment from chargeable overseas visitors. It also includes guidance to safeguard the health of those not entitled to free hospital treatment and new guidance on sharing information on NHS debtors to subject them to immigration sanctions.

    27 March 2015 | Department of Health
  • UNAIDS holds virtual consultation for its 2016–2021 Strategy

    UNAIDS is holding its first round of virtual consultations to develop its 2016–2021 Strategy. From 23 March to 2 April, the consultation process will be open to everyone to share information, ideas and experiences on how to accelerate rights-based, evidence-informed action to Fast-Track the AIDS response.

    26 March 2015 | UNAIDS
  • Charging non-EU visitors to the UK for GP appointments ‘would backfire’, researchers say

    Charging non-EU migrants for access to primary care would increase health risks to the rest of the population and place an even bigger financial burden on the NHS, experts from the London School of Hygiene and Tropical Medicine have warned.

    24 March 2015 | Pulse
  • KEI Europe asks Romanian government to issue compulsory licences on hepatitis C medicines

    For a country with a gross national income (GNI) per capita of $9,060, roughly one-quarter of the overall GNI per capita across the EU, the medicines are simply too costly to be within reach of patients in need, and put strains on the government's ability to provide reimbursements.

    23 March 2015 | Knowledge Ecology International
  • Indian generic companies should reject Gilead’s controversial hepatitis C ‘Anti-Diversion’ programme

    Ahead of a meeting in Jaipur, India next week between US pharmaceutical company Gilead Sciences and several Indian companies which have entered into an agreement with Gilead to produce hepatitis C drugs, Médecins Sans Frontières/Doctors Without Borders (MSF) urged the generic companies to reject a highly-controversial programme that could compromise people’s treatment and confidentiality.

    19 March 2015 | MSF
  • Gilead to require proof of citizenship to buy Sovaldi in poor countries

    Médecins Sans Frontières/Doctors Without Borders (MSF) is urging Gilead to drop some of the provisions. If Gilead won't, MSF suggests that generic drugmakers ignore some of the requirements, like demanding that patients provide proof of citizenship to fill a prescription.

    19 March 2015 | Fierce Pharma
  • $10 Copy of Gilead Blockbuster Sovaldi Appears in Bangladesh

    Incepta Pharmaceuticals Ltd. doesn’t have a license from Gilead and its version was launched last month, said Managing Director Abdul Muktadir. The company also aims to sell the drug overseas, including to parts of Southeast Asia and Africa.

    09 March 2015 | Bloomberg
  • EECA CAB positions in regards to Janssen, BMS, Gilead and ViiV policy

    EECA CAB (Community Advisory Board in Eastern Europe and Central Asia) has published its positions in regards to Janssen, BMS, ViiV and Gilead policy. The positions were developed on the results of the meetings with the companies during last year.

    09 March 2015 | EATG
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.